Avalo Therapeutics
AVTX
18 hedge funds and large institutions have $73.5M invested in Avalo Therapeutics in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.
11% more capital inflows, than outflows
Capital inflows: $2.35M | Capital outflows: $2.12M
0% more funds holding
Funds holding: 18 → 18 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
10.79% less ownership
Funds ownership: 64.68% → 53.89% (-11%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$1.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$310K |
| 3 |
Spark Investment Management
New York
|
+$274K |
| 4 |
BlackRock
New York
|
+$107K |
| 5 |
GSA Capital Partners
London,
United Kingdom
|
+$59.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridgeway Capital Management
Houston,
Texas
|
-$1.11M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$322K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$229K |
| 4 |
Virtu Financial
New York
|
-$103K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$86K |
AVTX Hedge Fund Activity: Q2 2018 in Review
18 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2018, worth a combined $73.5M — up 1.6% from $72.3M a quarter earlier.
Fund positioning in AVTX was balanced in Q2 2018: 6 funds opened new positions, 6 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, adding an estimated $1.5M. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $1.11M sold.
- 18 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $73.5M of Avalo Therapeutics stock for Q2 2018, up 1.6% quarter-over-quarter.
- 6 funds opened new Avalo Therapeutics positions in Q2 2018 and 6 closed out, a net change of 0 holders.
- The largest Avalo Therapeutics buyer in Q2 2018 was Armistice Capital, an estimated $1.5M added.
- The largest Avalo Therapeutics seller in Q2 2018 was Bridgeway Capital Management, an estimated $1.11M sold.
Based on aggregated 13F filings for Q2 2018.